Amyotrophic lateral sclerosis treatment with ultramicronized palmitoylethanolamide: A case report

CNS and Neurological Disorders - Drug Targets

Volumn 11, Issue 7, 2012, Pages 933-936

  Clemente, Simonetta ^a  

^a Macomer Rehabilitation Center   (Italy)

Author keywords

Electromyography; Mast cells; Microglia; Motor neuron disease; Neurodegeneration; Palmitoylethanolamide; Spinal inflammation

Indexed keywords

NORMAST; PALMIDROL; UNCLASSIFIED DRUG;

ADULT; AMYOTROPHIC LATERAL SCLEROSIS; ARTERIAL GAS; ARTICLE; BLOOD GAS ANALYSIS; BREATHING; CASE REPORT; DRUG DOSE INCREASE; ELECTROMYOGRAPHY; FASCICULATION; HUMAN; LUNG FUNCTION; MALE; MOTOR UNIT POTENTIAL; TREATMENT OUTCOME;

ADMINISTRATION, SUBLINGUAL; AMYOTROPHIC LATERAL SCLEROSIS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DIETARY SUPPLEMENTS; ENDOCANNABINOIDS; ETHANOLAMINES; HUMANS; MALE; MIDDLE AGED; PALMITIC ACIDS; TREATMENT OUTCOME;

EID: 84873158343     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/1871527311201070933     Document Type: Article

References (25)

1. Wood-Allum, C.; Shaw, P.J. Motor neurone disease: a practical update on diagnosis and management. Clin. Med., 2010, 10(3), 252-258.
2. Appel, S.H.; Zhao, W.; Beers, D.R.; Henkel, J.S. The microglialmotoneuron dialogue in ALS. Acta Myologica, 2011, 30(1) 4-8.
3. Ferraiuolo, L.; Kirby, J.; Grierson, A.J.; Sendtner, M.; Shaw, P.J. Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis. Nat. Rev. Neurol., 2011, 7(11), 616-630.
4. Aggarwal, S.; Cudkowicz, M. ALS drug development: reflections of the past and a way forward. Neurotherapeutics, 2008, 5(4), 516-527.
5. Schnabel, J. Neuroscience: standard model. Nature, 2008, 454(7205), 682-685.
6. Morren, J.A.; Galvez-Jimenez, N. Current and prospective diseasemodifying therapies for amyotrophic lateral sclerosis. Expert Opin. Investig. Drugs, 2012, 21(3), 297-320.
7. Di Marzo, V. Targeting the endocannabinoid system: to enhance or reduce? Nat. Rev. Drug Dis., 2008, 7(5), 438-455.
8. Costa, B.; Conti, S.; Giagnoni, G.; Colleoni, M. Therapeutic effect of the endogenous fatty acid amide, palmitoylethanolamide, in rat acute inflammation: inhibition of nitric oxide and cyclo-oxygenase systems. Br. J. Pharmacol., 2002, 137(4), 413-420.
9. Costa, B.; Comelli, F.; Bettoni, I.; Colleoni, M.; Giagnoni, G. The endogenous fatty acid amide, palmitoylethanolamide, has antiallodynic and anti-hyperalgesic effects in a murine model of neuropathic pain: involvement of CB1, TRPV1 and PPAR receptors and neurotrophic factors. Pain, 2008, 139(3), 541-550.
10. D'Agostino, G.; La Rana, G.; Russo, R.; Sasso, O.; Iacono, A.; Esposito, E.; Mattace, Raso G.; Cuzzocrea, S.; Loverme, J.; Piomelli, D.; Meli, R.; Calignano, A. Central administration of palmitoylethanolamide reduces hyperalgesia in mice via inhibition of NF-oB nuclear signalling in dorsal root ganglia. Eur. J. Pharmacol., 2009, 613(1-3) 54-59.
11. De Filippis, D.; Luongo, L; Cipriano, M.; Palazzo, E.; Cinelli, M.P.; de Novellis, V.; Maione, S.; Iuvone, T. Palmitoylethanolamide reduces granuloma-induced hyperalgesia by modulation of mast cell activation in rats. Mol. Pain, 2011, 7.
12. Esposito, E.; Paterniti, I.; Mazzon, E.; Genovese, T.; Di Paola, R.; Galuppo, M.; Cuzzocrea, S. Effects of palmitoylethanolamide on release of mast cell peptidases and neurotrophic factors after spinal cord injury. Brain Behav. Immun., 2011, 25(6), 1099-1112.
13. Skaper, S.D.; Buriani, A.; Dal Toso, R.; Petrelli, L.; Romanello, S.; Facci, L.; Leon, A. The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. Proc. Natl. Acad Sci USA, 1996, 93(9), 3984-3989.
14. Truini, A.; Biasiotta, A.; Di Stefano, G.; La Cesa, S.; Leone, C.; Cartoni, C.; Federico, V.; Petrucci, M.T.; Cruccu, G. Palmitoylethanolamide restores myelinated-fibre function in patients with chemotherapy-induced painful neuropathy. CNS Neurol. Disord. Drug Targets, 2012, 10(1), 916-920.
15. Gatti, A.; Lazzari, M.; Gianfelice, V.; Di Paolo, A.; Sabato, E.; Sabato, A.F. Palmitoylethanolamide in the treatment of chronic pain caused by different etiopathogeneses. Pain Med. 2012, In press.
16. Zinman, L.; Cudkowicz, M. Emerging targets and treatments in amyotrophic lateral sclerosis. Lancet Neurol., 2011, 10(5), 481-490.
17. Rothstein, J.D. Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann. Neurol., 2009, 65(Suppl. 1), S3-S9.
18. Graves, M.C.; Fiala, M.; Dinglasan, L.A.; Liu, N.Q.; Sayre, J.; Chiappelli, F.; van Kooten, C.; Vinters, H.V. Inflammation in amyotrophic lateral sclerosis spinal cord and brain is mediated by activated macrophages, mast cells and T cells. Amyotr. Lateral Scler. Other Motor Neuron Disord., 2004, 5(4), 213-219.
19. Fiala, M.; Chattopadhay, M.; La Cava, A.; Tse, E.; Masoumi, A.; Porter, V.; Wiedau-Pazos, M.; Sayre, J.; Ong, R.; Mahanian, M.; Koo, P.; Bae, S.; Micic, M.; Liu, P.T.; Rosenthal, M.J.; Fiala, M. IL-17A is increased in the serum and in spinal cord CD8 and mast cells of ALS patients. J. Neuroinflammation, 2010, 7, 76.
20. Centonze, D.; Rossi, S.; Finazzi-Agrò, A.; Bernardi, G.; Maccarrone, M. The (endo) cannabinoid system in multiple sclerosis and amyotrophic lateral sclerosis. Int. Rev. Neurobiol., 2007, 82, 171-186.
21. Witting, A.; Weydt, P.; Hong, S.; Kliot, M.; Moller, T.; Stella, N. Endocannabinoids accumulate in spinal cord of SOD1 G93A transgenic mice. J. Neurochem., 2004, 89(6), 1555-1557.
22. Bilsland, L.G.; Dick, J.R.; Pryce, G.; Petrosino, S.; Di Marzo, V.; Baker, D.; Greensmith, L. Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice. FASEB J., 2006, 20(7), 1003-1005.
23. Facci, L.; Dal Toso, R.; Romanello, S.; Buriani, A.; Skaper, S.D.; Leon, A. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc. Natl. Acad. Sci. USA, 1995, 92(8), 3376-3380.
24. Franklin, A.; Parmentier-Batteur, S.; Walter, L.; Greenberg, D.A.; Stella, N. Palmitoylethanolamide increases after focal cerebral ischemia and potentiates microglial cell motility. J. Neurosci., 2003, 23(21), 7767-7775.
25. Schäbitz, W.R.; Giuffrida, A.; Berger, C.; Aschoff, A.; Schwaninger, M.; Schwab, S.; Piomelli, D. Release of fatty acid amides in a patient with hemispheric stroke: a microdialysis study. Stroke, 2002, 33(8), 2112-2114.